Section Arrow
ALLO.NASDAQ
- Allogene Therapeutics
Quotes are at least 15-min delayed:2026/07/24 09:43 EDT
Regular Hours
Last
 1.8
-0.02 (-1.10%)
Day High 
1.84 
Prev. Close
1.82 
1-M High
2.25 
Volume 
156.20K 
Bid
1.8
Ask
1.81
Day Low
1.795 
Open
1.83 
1-M Low
1.74 
Market Cap 
628.18M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.86 
20-SMA 1.99 
50-SMA 2.01 
52-W High 4.46 
52-W Low 0.9842 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.77/-0.97
Enterprise Value
703.23M
Balance Sheet
Book Value Per Share
0.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZVRAZevra Therapeutics9.645-2.875-22.96%6.23PE
CDXSCodexis1.52-0.47-23.62%-- 
IOVAIovance Biotherapeutics5.03-0.1-1.95%-- 
MNKDMannKind Corp4.03+0.14+3.60%-- 
SMMTSummit Therapeutics13.79-1.19-7.94%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.